Myosteatosis Is Associated With Frailty and Poor Physical Function in Patients Undergoing Liver Transplant Evaluation: A Cohort Study

Heidi E. Johnston,Melita Andelkovic,Hannah L. Mayr,Yanyan Chen,Aaron P. Thrift,Graeme A. Macdonald,Ingrid J. Hickman
DOI: https://doi.org/10.1111/ctr.70034
2024-12-05
Clinical Transplantation
Abstract:Introduction Myosteatosis is fat infiltration within skeletal muscle. The impact of myosteatosis on physical function and clinical outcomes in patients referred for liver transplantation (LT) is unclear. We explored associations between myosteatosis and sarcopenia, frailty, physical function, and pre‐ and early post‐LT outcomes. Methods Myosteatosis was assessed by computed tomography (CT) in 237 patients referred for LT (March 2018 to September 2022). Chi‐square/Fishers exact tests and multivariable regression compared myosteatosis and sarcopenia, frailty (liver frailty index), physical function (short physical performance battery, SPPB); and associations with pre‐LT unplanned hospitalizations, post‐LT surgical complications (Clavien–Dindo grade ≥ 3), and LT admission length of stay (LOS). Kaplan–Meier and Cox‐proportional hazards models explored myosteatosis and time to LT and unplanned admission. Fine–Gray model evaluated the competing risks of receiving an LT. Results Myosteatosis was present in 74 (31%) patients. Patients with myosteatosis were 2.5 times (95% confidence interval [CI] 1.1–5.7, p = 0.03) more likely to be frail, and 3.0 times (95% CI 1.6–5.6, p
surgery,transplantation
What problem does this paper attempt to address?